Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

6.4K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.4K
The Ras Gene02:38

The Ras Gene

6.5K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

4.1K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

7.7K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
7.7K
Abnormal Proliferation02:23

Abnormal Proliferation

4.7K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Linking deubiquitination to pyroptosis: new perspectives from OTUB1 in hepatocellular carcinoma.

Journal of gastrointestinal oncology·2026
Same author

Molecular insights and therapeutic implications for the tumor suppressor role of LKB1 in non-small cell lung cancer.

Cancer letters·2026
Same author

Discovery of New OTUB1 Covalent Ligands via Structure-Activity Relationship Studies for Targeted Protein Stabilization.

Journal of medicinal chemistry·2026
Same author

Reactive oxygen species (ROS) in cancer: from mechanism to therapeutic implications.

Signal transduction and targeted therapy·2026
Same author

Molecular insights for the tumor suppressor role of SPOP in prostate cancer.

Biochimica et biophysica acta. Reviews on cancer·2026
Same author

Protein neddylation in lung tumorigenesis: Target validation and targeted therapy.

Fundamental research·2026

Related Experiment Video

Updated: Oct 6, 2025

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.2K

Acetylation-dependent regulation of BRAF oncogenic function.

Xiangpeng Dai1, Xiaoling Zhang2, Qing Yin3

  • 1Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA; Laboratory of Organ Regeneration & Transplantation of the Ministry of Education, The First Hospital of Jilin University, Changchun 130061, PR China; National-local Joint Engineering Laboratory of Animal Models for Human Diseases, Changchun, Jilin 130061, PR China.

Cell Reports
|January 19, 2022
PubMed
Summary

Acetylation by p300 activates BRAF kinase, promoting cancer cell growth and drug resistance. This acetylation is reversed by SIRT1, offering new biomarkers for melanoma treatment.

Keywords:
BRAFSIRT1acetylationmelanomap300

More Related Videos

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells
06:44

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

Published on: March 1, 2024

1.3K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

324

Related Experiment Videos

Last Updated: Oct 6, 2025

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.2K
Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells
06:44

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

Published on: March 1, 2024

1.3K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

324

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Aberrant BRAF activation, particularly the BRAFV600E mutation, is common in cancers.
  • Regulation of BRAF kinase activity beyond phosphorylation and ubiquitination is not well understood.

Purpose of the Study:

  • To investigate the role of post-translational modifications, specifically acetylation, in BRAF kinase regulation.
  • To identify the enzymes involved in BRAF acetylation and deacetylation and their impact on cancer.

Main Methods:

  • Investigated BRAF K601 acetylation using biochemical assays.
  • Assessed the effects of p300 (acetyltransferase) and SIRT1 (deacetylase) on BRAF activity.
  • Utilized patient-derived mutations and cell proliferation assays.

Main Results:

  • p300 acetylates BRAF at K601, activating its kinase activity.
  • SIRT1 antagonizes p300-mediated BRAF K601 acetylation.
  • K601 acetylation promotes BRAF dimerization and enhances melanoma cell proliferation.
  • K601 acetylation contributes to resistance against BRAFV600E inhibitors.
  • A patient-derived K601E mutation mimics acetylation to increase BRAF activity.

Conclusions:

  • Uncovered a novel acetylation-dependent regulatory mechanism for BRAF kinase.
  • p300-mediated K601 acetylation is a key driver of melanoma proliferation and drug resistance.
  • p300 hyperactivation or SIRT1 deficiency may serve as biomarkers for ERK activation in melanoma.